Market News How it works Learn FAQ
| GPUS 0.1689 34.05% | XXII 0.1977 -8.34% | SHFS 0.1324 -61.39% | NVD 4.19 0.96% | LUCD 0.411 25.42% | SPCX 147.49 1.89% | T 20.93 -7.96% | SOXL 83.56 1.77% | NU 15.16 2.92% | NOK 8.14 3.30% | EWZ 42.59 1.77% | NVDA 210.96 -0.59% | RIME 0.106 -12.90% | INTC 86.96 1.72% | TSLG 4.87 -1.62% | AAL 12.11 -3.89% | BBD 4.07 3.04% | STLA 4.06 -4.81% | SOXS 52.46 -1.85% | RWM 14.55 0.34% | HYG 77.05 -0.06% | MYND 0.24 47.42% | BITO 10.83 -0.28% | SPDN 8.54 0.47% | YFOR 0.2236 -1.58% | RBNE 0.19 -2.56% | TQQQ 66.29 -0.20% | VZ 44.66 -1.19% | TSLL 9.76 -1.21% | SPTI 27.63 -0.11% | YMAT 2.05 6.77% | CRWV 54.235 -2.46% | INFY 12.35 -6.58% | RIG 6.41 5.43% | F 11.6 -2.85% | SQQQ 39.68 0.20% | AIOK 12.02 182.82% | ONDS 6.2 2.99% | AAPL 347.725 -0.14% | LABT 0.31 -36.67% | CDE 13.45 -3.10% | PCG 12.63 -2.70% | GRAB 2.79 -2.11% | SOFI 14.615 -1.05% | XLE 69.33 2.60% | IREN 24.905 -2.37% | QID 14.55 0.14% | RKT 11.73 -0.09% | WULF 11.32 0.00% | BE 193.3 -11.24%
GRGRAIL Inc. logo

GRAIL Inc. (GRAL)

NASDAQ · Currency in USD
$132.55 ▲ +5.49 (+4.32%)
At close: Oct 23, 4:00 PM ET. Market closed.
$135.19 ▲ +2.64 (+1.99%)
After hours: Oct 23, 7:53 PM ET

Summary

Previous Close
$127.06
Open
$127.09
Day's Range
$124.32 – $135.94
52 Week Range
$41.50 – $166.48
Volume
575,003
Avg. Volume
867,380
Market Cap
$5.92B
Beta (5Y Monthly)
3.25
PE Ratio (TTM)
--
EPS (TTM)
-$9.08
Earnings Date
Nov 4, 2026
Forward Dividend & Yield
--
Ex-Dividend Date
--
1y Target Est
$107.88

Profile: GRAIL Inc.

Sector
Healthcare
Industry
Medical - Diagnostics & Research
Full-time employees
910
CEO
Joshua J. Ofman
Website
grail.com

GRAIL, Inc., a commercial-stage healthcare company, provides multi-cancer early detection testing and services in the United States and internationally. It offers Galleri, a cancer screening test for asymptomatic individuals over 50 years of age; and a diagnostic aid for cancer tests to accelerate diagnostic resolution for patients with clinical suspicion of cancer. The company also provides development services, including support for ongoing clinical studies, pilot testing, research, and therapy development.

Earnings

Next report: Wed, Nov 4, 2026
EPS estimate -$2.45 · Revenue est. $44.21M
DateEst.Actual
Aug 5, 2026-$2.66-$2.56Beat
May 5, 2026-$2.76-$2.29Beat
Feb 19, 2026-$3.33-$2.44Beat
Nov 12, 2025-$3.36-$2.46Beat
Aug 12, 2025-$3.14-$3.18Miss
May 13, 2025-$4.03-$3.10Beat

Analyst view

Consensus price target
$107.88 ▼ -18.6%
Range $56.00 – $175.00
Rating: Buy
Buy 63% · Hold 38% · Sell 0%

Get free alerts on GRAL and big market moves

Free special alerts by text & email on new investment opportunities, buyouts and the stocks moving most, in plain English.
Get free stock alerts →
Data: Financial Modeling Prep. For information only, not investment advice.